Brian Belmontes

1.6k total citations
22 papers, 757 citations indexed

About

Brian Belmontes is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Brian Belmontes has authored 22 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Immunology. Recurrent topics in Brian Belmontes's work include Cancer-related gene regulation (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Growth Hormone and Insulin-like Growth Factors (4 papers). Brian Belmontes is often cited by papers focused on Cancer-related gene regulation (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Growth Hormone and Insulin-like Growth Factors (4 papers). Brian Belmontes collaborates with scholars based in United States, Switzerland and Malaysia. Brian Belmontes's co-authors include Pedro J. Beltran, Robert Radinsky, Elaina Cajulis, Frank J. Calzone, Gordon Moody, Patricia L. Mitchell, Yong Suk Chung, Steven Vonderfecht, Petia Mitchell and Richard Kendall and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Brian Belmontes

21 papers receiving 742 citations

Peers

Brian Belmontes
Amy Prawira Canada
Hamid Emamekhoo United States
Yanina Jansen Belgium
Dijana Djureinovic Sweden
Mareyuki Endoh Japan
Prateek Mendiratta United States
Ran Xie United States
Antonio López-Beltrán Spain
Antonella Ingrosso Italy
Jacob J. Orme United States
Amy Prawira Canada
Brian Belmontes
Citations per year, relative to Brian Belmontes Brian Belmontes (= 1×) peers Amy Prawira

Countries citing papers authored by Brian Belmontes

Since Specialization
Citations

This map shows the geographic impact of Brian Belmontes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Belmontes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Belmontes more than expected).

Fields of papers citing papers by Brian Belmontes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Belmontes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Belmontes. The network helps show where Brian Belmontes may publish in the future.

Co-authorship network of co-authors of Brian Belmontes

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Belmontes. A scholar is included among the top collaborators of Brian Belmontes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Belmontes. Brian Belmontes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Su, Chun, Rui Yuan, Jiamiao Lu, et al.. (2025). Abstract 4225: Targeting RNA splicing sensitizes MTAP-deleted cancers to MTA-cooperative PRMT5 inhibitors. Cancer Research. 85(8_Supplement_1). 4225–4225. 2 indexed citations
2.
Garbett, Damien, Arjun A. Rao, Manfréd M. Fischer, et al.. (2024). 216 (PB204): The mechanistic basis of both deep and durable antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors. European Journal of Cancer. 211. 114734–114734. 1 indexed citations
3.
4.
Fischer, Marcus, Brian Belmontes, Yevgeniy Freyman, et al.. (2023). Abstract 1644: Dual inhibition of MAT2A and PRMT5 delivers synergistic anti-tumor responses in preclinical models of MTAP-deleted cancer. Cancer Research. 83(7_Supplement). 1644–1644. 4 indexed citations
5.
Liu, Xian, Jason S. Eng, Jessica Orf, et al.. (2022). Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunity. Cancer Immunology Immunotherapy. 72(5). 1327–1335. 14 indexed citations
6.
Zhang, Qiming, Siyuan Liu, Yedan Liu, et al.. (2022). Liver Metastasis Modulate Responses of Suppressive Macrophages and Exhausted T Cells to Immunotherapy Revealed by Single Cell Sequencing. SHILAP Revista de lepidopterología. 3(4). 2200002–2200002. 5 indexed citations
7.
Lock, Richard B., Kathryn Evans, Eric J. Earley, et al.. (2022). Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia. Blood. 140(Supplement 1). 11690–11691. 1 indexed citations
8.
Belmontes, Brian, Siyuan Liu, Jodi Moriguchi, et al.. (2022). Abstract 1807: The discovery and preclinical characterization of the MTA cooperative PRMT5 inhibitor AM-9747. Cancer Research. 82(12_Supplement). 1807–1807. 4 indexed citations
9.
Belmontes, Brian, Deepali V. Sawant, Wendy Zhong, et al.. (2021). Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors. Science Translational Medicine. 13(608). 72 indexed citations
10.
O’Brien, Sarah A., Jessica Orf, Katarzyna M. Skrzypczynska, et al.. (2021). Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment. Cancer Immunology Immunotherapy. 70(8). 2401–2410. 37 indexed citations
11.
Moesta, Achim K., Keegan S. Cooke, Julia Piasecki, et al.. (2017). Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade. Clinical Cancer Research. 23(20). 6190–6202. 81 indexed citations
12.
13.
Moody, Gordon, Brian Belmontes, Wei Wang, et al.. (2016). Antibody‐mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo. International Journal of Cancer. 139(6). 1340–1349. 19 indexed citations
14.
Beltran, Pedro J., Frank J. Calzone, Petia Mitchell, et al.. (2014). Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy. Clinical Cancer Research. 20(11). 2947–2958. 41 indexed citations
15.
Carnahan, Josette, Pedro J. Beltran, Carol Babij, et al.. (2010). Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth. Molecular Cancer Therapeutics. 9(8). 2399–2410. 58 indexed citations
16.
Carnahan, Josette, Pedro J. Beltran, Carol Babij, et al.. (2010). Abstract 21: Selective and potent inhibitors of the mutant B-Raf pathway paradoxically stimulate the MAPK pathway in wild-type B-Raf cells. Cancer Research. 70(8_Supplement). 21–21. 2 indexed citations
17.
Beltran, Pedro J., Petia Mitchell, Elaina Cajulis, et al.. (2009). AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular Cancer Therapeutics. 8(5). 1095–1105. 113 indexed citations
18.
Freeman, Daniel J., Tammy L. Bush, Brian Belmontes, et al.. (2009). Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Molecular Cancer Therapeutics. 8(6). 1536–1546. 22 indexed citations
19.
Beltran, Pedro J., Patricia L. Mitchell, Gordon Moody, et al.. (2008). Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. Journal of Clinical Oncology. 26(15_suppl). 4617–4617. 197 indexed citations
20.
Coxon, Angela, Tammy L. Bush, Douglas C. Saffran, et al.. (2008). Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors. Clinical Cancer Research. 15(1). 110–118. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amy Prawira Breakdown of academic impact, for papers by Hamid Emamekhoo Breakdown of academic impact, for papers by Yanina Jansen Breakdown of academic impact, for papers by Dijana Djureinovic Breakdown of academic impact, for papers by Mareyuki Endoh Breakdown of academic impact, for papers by Prateek Mendiratta Breakdown of academic impact, for papers by Ran Xie Breakdown of academic impact, for papers by Antonio López-Beltrán Breakdown of academic impact, for papers by Antonella Ingrosso Breakdown of academic impact, for papers by Jacob J. Orme
Rankless by CCL
2026